Director and Professor, Biological Sciences Division, Pacific Northwest National Laboratory
Biography
Dr. Karin Rodland joined the Biological Sciences Division at the Pacific Northwest National Laboratory in October 2001, after serving seventeen years on the faculty of Oregon Health Sciences University. As Chief Scientist for Biomedical Research at PNNL, she has promoted the application of PNNL's traditional strengths in mass spectrometry, proteomics, and systems biology to important problems in biomedical research. She is currently the PNNL co-Director of the OHSU-PNNL Precision Medicine Innovation CoLaboratory, a joint effort dedicated to improving patient outcomes through the integration of cutting edge technologies in integrated omics, imaging, and data analysis to advance the goals of precision medicine.
Dr. Rodland's own research focuses on signal transduction pathways that regulate proliferation in normal and malignant cells. She was the first to recognize the role of the calcium-sensing receptor in modulating proliferation in response to small molecules in the extracellular environment. Since joining PNNL, she has adopted a systems biology approach to signal transduction and has become a recognized expert in the field of proteomics and cancer biomarkers. She is a full member of the National Cancer Institute's Early Detection Research Network, and is the chair of the Clinical Proteomics Tumor Analysis Consortium Steering Committee. She has served as Chair of the Cancer Biomarkers Study Section for the NIH, as well as the Department of Defense Congressionally Directed Medical Research Program Integration Panels for both Ovarian and Breast Cancer Research.
Dr. Rodland's own research focuses on signal transduction pathways that regulate proliferation in normal and malignant cells. She was the first to recognize the role of the calcium-sensing receptor in modulating proliferation in response to small molecules in the extracellular environment. Since joining PNNL, she has adopted a systems biology approach to signal transduction and has become a recognized expert in the field of proteomics and cancer biomarkers. She is a full member of the National Cancer Institute's Early Detection Research Network, and is the chair of the Clinical Proteomics Tumor Analysis Consortium Steering Committee. She has served as Chair of the Cancer Biomarkers Study Section for the NIH, as well as the Department of Defense Congressionally Directed Medical Research Program Integration Panels for both Ovarian and Breast Cancer Research.
